These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23725605)

  • 1. Advances in the development of vaccines for Alzheimer's disease.
    Lambracht-Washington D; Rosenberg RN
    Discov Med; 2013 May; 15(84):319-26. PubMed ID: 23725605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abeta immunotherapy and other means to remove amyloid.
    McGeer EG; McGeer PL
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):569-73. PubMed ID: 16266289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
    Conway KA; Baxter EW; Felsenstein KM; Reitz AB
    Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.
    Yu YZ; Xu Q
    Hum Vaccin Immunother; 2016 Nov; 12(11):2801-2804. PubMed ID: 27379885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease?
    Lemere CA; Oh J; Stanish HA; Peng Y; Pepivani I; Fagan AM; Yamaguchi H; Westmoreland SV; Mansfield KG
    Rejuvenation Res; 2008 Apr; 11(2):321-32. PubMed ID: 18341428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.
    Ono K; Tsuji M
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 T cells in immunity and immunotherapy of Alzheimer's disease.
    Monsonego A; Nemirovsky A; Harpaz I
    Immunology; 2013 Aug; 139(4):438-46. PubMed ID: 23534386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.